Literature DB >> 9051015

Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging?

B Hamm1, A E Mahfouz, M Taupitz, D G Mitchell, R Nelson, E Halpern, A Speidel, K J Wolf, S Saini.   

Abstract

PURPOSE: To compare dynamic gadolinium-enhanced with unenhanced magnetic resonance (MR) imaging in detection of liver metastases.
MATERIALS AND METHODS: Two groups of patients were prospectively examined with unenhanced and dynamic gadolinium-enhanced MR imaging. The first group (n = 48) had proved liver metastases; the second group (n = 49) did not. One set of unenhanced and one set of gadolinium-enhanced MR images were selected per patient. Three independent, blinded readers assessed the images for presence, number, location, and conspicuity of lesions. Data were analyzed with receiver operating characteristic curves, and contrast-to-noise ratios were calculated for the images.
RESULTS: There was no statistically significant difference between the use of unenhanced and gadolinium-enhanced MR images in the differentiation of patients with from patients without metastases. The numbers of false-positive and false-negative diagnoses of individual lesions were higher (not statistically significant) with dynamic MR images than with unenhanced MR images. At dynamic MR imaging, contrast-to-noise ratio was highest in the early phase (30 seconds after injection of the contrast agent) but was not significantly different from the contrast-to noise ratio of the T2-weighted images.
CONCLUSION: Dynamic gadolinium-enhanced MR imaging showed no improvement over unenhanced MR imaging in detectability of liver metastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9051015     DOI: 10.1148/radiology.202.3.9051015

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Utility of 3D magnetic resonance imaging in preoperative evaluation of hepatobiliary diseases.

Authors:  R Tongdee; V R Narra; E P Oliveira; W Chapman; K M Elsayes; J J Brown
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

2.  Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

Authors:  C S Peña; S Saini; R L Baron; B A Hamm; G Morana; R Caudana; A Giovagnoni; A Villa; A Carriero; D Mathieu; M W Bourne; M A Kirchin; G Pirovano; A Spinazzi
Journal:  Korean J Radiol       Date:  2001 Oct-Dec       Impact factor: 3.500

3.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

4.  Follow-up result afters negative findings on unenhanced hepatic MR imaging for hepatic metastasis from rectal cancer.

Authors:  Joon Seok Lim; Myeong-Jin Kim; Kang Young Lee; Nam Kyu Kim; Jin-Sub Choi; Joo Hee Kim; Young Taik Oh; Won Ho Kim; Ki Whang Kim
Journal:  Korean J Radiol       Date:  2004 Oct-Dec       Impact factor: 3.500

5.  Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT.

Authors:  Carlo Bartolozzi; Francescamaria Donati; Dania Cioni; Carlo Procacci; Giovanni Morana; Antonio Chiesa; Luigi Grazioli; Giorgio Cittadini; Giuseppe Cittadini; Andrea Giovagnoni; Giovanni Gandini; Jochen Maass; Riccardo Lencioni
Journal:  Eur Radiol       Date:  2003-08-09       Impact factor: 5.315

6.  Detection of colorectal liver metastases: prospective comparison of unenhanced and ferumoxides-enhanced magnetic resonance imaging at 1.5 T, dual-phase spiral CT, and spiral CT during arterial portography.

Authors:  R Lencioni; F Donati; D Cioni; A Paolicchi; A Cicorelli; C Bartolozzi
Journal:  MAGMA       Date:  1998-12       Impact factor: 2.310

7.  Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection.

Authors:  Caecilia S Reiner; Paul Stolzmann; Lars Husmann; Irene A Burger; Martin W Hüllner; Niklaus G Schaefer; Paul M Schneider; Gustav K von Schulthess; Patrick Veit-Haibach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-18       Impact factor: 9.236

Review 8.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

Review 9.  Liver metastases of colorectal cancer: US, CT or MR?

Authors:  Wolfgang Schima; Christiane Kulinna; Herbert Langenberger; Ahmed Ba-Ssalamah
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.